EU Union grants orphan drug status to GLPG1690 for idiopathic pulmonary fibrosis

Release Date: 13-Nov-2016

Galapagos, a bio-technology company dedicated to produce small molecule medicines with novel modes of action, declared that its novel medication GLPG1690 has been approved as orphan drug by European Commission for the treatment of idiopathic pulmonary fibrosis (IPF).


IPF is a chronic fibrotic disorder of lungs affecting people above the age of 40 years. IPF is a rare disease as its prevalence has been estimated to be 30 per 100,000 people in Europe as well as US. Presently, there are no medications available to cure IPF.


The FDA and EMA’s designation of orphan status is granted to encourage new developments and therapies for rare diseases and disorders. Orphan status can be granted to those diseases that are rare. These incentives include protocol assistance, i.e. scientific advice specific for designated orphan medicines, and 10 years of market exclusivity once the medicine is on the market.


For Orphan Drug Clinical Insight Reports Contact:

Need custom market research solution? We can help you with that too.